NEW YORK, NY / ACCESSWIRE / February 17, 2022 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
CONTACT JAKUBOWITZ ABOUT FENC:
https://claimyourloss.com/securities/fennec-pharmaceuticals-inc-loss-submission-form-2/?id=23796&from=1
Class Period : May 28, 2021 – November 26, 2021
Lead Plaintiff Deadline : April 11, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application (“NDA”); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Astra Space Inc. f/k/a Holicity Inc. (NASDAQ:ASTR)
CONTACT JAKUBOWITZ ABOUT ASTR:
https://claimyourloss.com/securities/astra-space-inc-f-k-a-holicity-inc-loss-submission-form/?id=23796&from=1
Class Period : February 2, 2021 – December 29, 2021
Lead Plaintiff Deadline : April 11, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Astra cannot launch “anywhere”; (2) Astra significantly overstated its addressable market; (3) Astra overstated the effectiveness of its designs and reliability; (4) Astra significantly overstated its plans for diversification and its broadband constellation plan; and (5) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.
Acutus Medical, Inc. (NASDAQ:AFIB)
CONTACT JAKUBOWITZ ABOUT AFIB:
https://claimyourloss.com/securities/acutus-medical-inc-loss-submission-form/?id=23796&from=1
This lawsuit is on behalf of all purchasers of Acutus common stock between May 13, 2021 and November 11, 2021, inclusive.
Lead Plaintiff Deadline : April 18, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) a material percentage of the Company’s AcQMap imaging and mapping systems under evaluation had been randomly installed at sites with little, if any, consideration given to whether the healthcare providers at the selected locations were likely to adopt, or desire, the Company’s products; (b) a material percentage of the AcQMap systems under evaluation had been installed in locations where the Company did not possess the infrastructure necessary to appropriately educate, train, and support medical service providers on the system’s operations; (c) as a result of (a) and (b) above, defendants were in the process of designing a strategic plan to terminate and relocate approximately 20% of then-existing AcQMap systems evaluation arrangements; (d) the Company’s management discussion and analysis was materially false and misleading and failed to disclose that the termination and relocation of approximately 20% of existing AcQMap systems evaluation arrangements was reasonably likely to have a material adverse effect on the Company’s 2021 financial results; and (e) the Company’s risk factor discussions were materially false and misleading and made reference to potential risks without disclosing that such risks were then-existing or adequately describing the specific nature of the risks then facing the Company.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE : Jakubowitz Law
View source version on accesswire.com:
https://www.accesswire.com/689263/LAWSUITS-FILED-AGAINST-FENC-ASTR-and-AFIB–Jakubowitz-Law-Pursues-Shareholders-Claims